IL149064A0 - Method for protecting normal cells from cytotoxicity of chemotherapeutic agents - Google Patents

Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Info

Publication number
IL149064A0
IL149064A0 IL14906400A IL14906400A IL149064A0 IL 149064 A0 IL149064 A0 IL 149064A0 IL 14906400 A IL14906400 A IL 14906400A IL 14906400 A IL14906400 A IL 14906400A IL 149064 A0 IL149064 A0 IL 149064A0
Authority
IL
Israel
Prior art keywords
normal cells
anticancer
cytotoxicity
chemotherapeutic agents
alpha
Prior art date
Application number
IL14906400A
Other languages
English (en)
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of IL149064A0 publication Critical patent/IL149064A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
IL14906400A 1999-10-12 2000-10-11 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents IL149064A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15912399P 1999-10-12 1999-10-12
PCT/US2000/028250 WO2001026645A1 (en) 1999-10-12 2000-10-11 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Publications (1)

Publication Number Publication Date
IL149064A0 true IL149064A0 (en) 2002-11-10

Family

ID=22571170

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14906400A IL149064A0 (en) 1999-10-12 2000-10-11 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Country Status (8)

Country Link
EP (1) EP1223923B1 (enExample)
JP (1) JP4780885B2 (enExample)
AT (1) ATE462423T1 (enExample)
AU (1) AU780844B2 (enExample)
CA (1) CA2387539C (enExample)
DE (1) DE60044092D1 (enExample)
IL (1) IL149064A0 (enExample)
WO (1) WO2001026645A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548553B2 (en) 1997-10-03 2003-04-15 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
CA2366750C (en) * 1999-04-02 2010-06-01 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
US6541475B2 (en) * 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
JP2004510761A (ja) 2000-10-05 2004-04-08 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 増殖性疾病を治療するための置換（ｅ）−スチリルベンジルスルホン
US6833480B2 (en) 2001-02-27 2004-12-21 Temple University - Of The Commonwealth System Of Higher Education (Z)-styrylbenzylsulfones and pharmaceutical uses thereof
WO2002069892A2 (en) * 2001-02-28 2002-09-12 Temple University Of The Commonwealth System Of Higher Education METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
ES2373945T3 (es) * 2002-02-28 2012-02-10 Temple University - Of The Commonwealth System Of Higher Education Bencilsulfonas de (e)-2,6-dialcoxiestirilo amino sustituido sustituidas en 4 para tratar trastornos proliferativos.
CA2546495C (en) * 2003-11-14 2012-10-09 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
NZ565561A (en) * 2005-07-29 2011-01-28 Onconova Therapeutics Inc Formulation of radioprotective alpha, beta unsaturated aryl sulfones
EP2091527B1 (en) * 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
CN118239868A (zh) * 2019-07-18 2024-06-25 华夏生生药业(北京)有限公司 氨基甲酸酯取代的苯乙烯基砜类化合物及其制备方法和用途
CN111253935B (zh) * 2019-12-24 2022-12-13 安徽大学 一种双通道检测极性和粘度的双光子荧光探针及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
EP0439421A1 (de) * 1990-01-23 1991-07-31 Ciba-Geigy Ag Mikrobizide Mittel
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
IL135438A (en) * 1997-10-03 2005-12-18 Univ Temple Pharmaceutical compositions containing styrl sulfones and some such novel styryl sulfone compounds with anticancer activity

Also Published As

Publication number Publication date
ATE462423T1 (de) 2010-04-15
DE60044092D1 (de) 2010-05-12
AU1198901A (en) 2001-04-23
CA2387539C (en) 2010-09-21
EP1223923A1 (en) 2002-07-24
AU780844B2 (en) 2005-04-21
EP1223923A4 (en) 2007-09-05
WO2001026645A1 (en) 2001-04-19
JP4780885B2 (ja) 2011-09-28
EP1223923B1 (en) 2010-03-31
CA2387539A1 (en) 2001-04-19
JP2003511412A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
IL149064A0 (en) Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
EP1370253B8 (en) Use of alpha, beta unsaturated aryl sulfones for protecting cells and tissues from ionizing radiation toxicity
WO2005044181A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
de Carvalho Melo-Cavalcante et al. Retinol palmitate and ascorbic acid: Role in oncological prevention and therapy
EP2295063A8 (en) Compositions and the use thereof the treatment of mitochondrial diseases
WO2004045523A3 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
ES2062155T3 (es) Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.
CA2560058A1 (en) A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
NO20015063D0 (no) En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten
AR026560A1 (es) Recubrimiento
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
ES2086313T3 (es) Nuevos derivados de xantina con efecto antagonista de adenosina.
UY30190A1 (es) Profarmacos mejorados de analogos de cc-1065
AP2004003120A0 (en) Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent
PT2038290E (pt) Moduladores de receptor do tipo toll 7
WO2005065074A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
ES2072881T3 (es) Procedimiento de preparacion de glicoconjugados de fosforamida mostaza e isofosforamida mostaza.
WO2001082949A3 (en) Method of reducing side effects of chemotherapy in cancer patients
CA2288059A1 (en) Method of treating malignancies
SI1615638T1 (sl) Uporaba derivatov 7-nitro-2,1,3-benzoksadiazola pri terapiji proti raku
WO2003061572A3 (en) Anti-inflammatory formulations
BE1000723A4 (fr) Utilisation de gangliosides exogenes dans des maladies tumorales comme facteur de protection contre la toxicite de medicaments antitumoraux.
WO2008006974A3 (fr) Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoïetiques contre la toxicite hematologique des agents chimiotherapeutiques.
WO2000059488A3 (en) Enhanced tissue and subcellular delivery of vitamin e compounds
AR023282A1 (es) Derivados de higromicina

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed